AbbVie Inc.





Real-time Estimate Cboe BZX 02:27:15 2023-12-07 pm EST Intraday chart for AbbVie Inc. 5-day change 1st Jan Change
147.56 USD +0.81% +3.72% -8.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Drop Thursday Afternoon MT
AbbVie-Cerevel Deal Makes 'Strategic Sense,' Mizuho Says MT
Sector Update: Health Care MT
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say RE
Bain scores over tenfold return with $8.7 billion Cerevel sale RE
Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook MT
AbbVie to focus on smaller deals after buying spree RE
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs MT
Trending : AbbVie to Buy Cerevel for $45 a Share DJ
Are rate cuts are coming early next year?
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout RE
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research MT
Transcript : AbbVie Inc., Cerevel Therapeutics Holdings, Inc. - M&A Call CI
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data DJ
AbbVie: acquisition of Cerevel Therapeutics CF
Cerevel options trading surge before AbbVie deal news raises eyebrows RE
AbbVie to buy drug developer Cerevel for $8.7 billion RE
Health Flat as Obesity-Drug Stock Craze Eases -- Health Care Roundup DJ
AbbVie Signs $8.7 Billion Deal to Acquire Cerevel Therapeutics MT
AbbVie Signs Deal to Buy Cerevel Therapeutics for $45/Share Cash, or Total Equity Value of About $8.7 Billion; Deal Seen Adding to AbbVie Earnings Beginning in 2030 MT
AbbVie Reportedly Near Deal to Acquire Cerevel Therapeutics, According to Reuters; AbbVie Could Pay About $45 Per Share for Cerevel, Report Says MT
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion -- Update DJ
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion DJ
AbbVie Close to $8 Billion Deal for Cerevel Therapeutics, Sources Say, Reuters Reports DJ
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-8.62% 258 B $
+60.11% 530 B $
+42.05% 438 B $
-11.63% 377 B $
-5.96% 268 B $
-14.13% 230 B $
+0.79% 200 B $
-9.98% 198 B $
-43.75% 163 B $
+3.59% 144 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock AbbVie Inc. - Nyse
  4. News AbbVie Inc.
  5. AbbVie Unit Allergan's Phase 3 Trial of Botox to Treat Platysma Prominence Meets Primary, Secondary Endpoints
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits